Antipsychotic agents in patients with dementia

Pharmacotherapy

Volumn 20, Issue 1 I, 2000, Pages 23-33

  Defilippi, Jennifer L ^a   Crismon, M Lynn ^a  

^a UNIVERSITY OF TEXAS AT AUSTIN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETOPHENAZINE; HALOPERIDOL; NEUROLEPTIC AGENT; OLANZAPINE; PHENOTHIAZINE; RISPERIDONE; THIORIDAZINE; TRIFLUOPERAZINE;

ALGORITHM; CLINICAL FEATURE; DEMENTIA; DRUG EFFICACY; DRUG INDUCED DISEASE; DRUG SAFETY; HUMAN; MOTOR DYSFUNCTION; REVIEW; SEDATION;

EID: 0033987833     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1592/phco.20.1.23.34661     Document Type: Review

References (43)

1. Chen JY, Stern Y, Sano M, et al. Cumulative risks of developing extrapyramidal signs, psychosis, or myoclonus in the course of Alzheimer's disease. Arch Neurol 1991;48:1141-3.
2. Borson S, Raskind MA. Clinical features and pharmacologic treatment of behavioral symptoms of Alzheimer's disease. Neurology 1997;48(suppl 6):S17-24.
3. Docherty JP, Frances A, Kahn DA. Treatment of agitation in older persons with dementia: the expert consensus guideline series Postgrad Med Special Report 1998;1-88.
4. Omnibus Reconciliation Act of 1987. PL 100-203, December 22, 1987.
5. Saltz BL, Woerner MG, Kane JM, et al. Prospective study of tardive dyskinesia frequency in the elderly. JAMA 1991;266:2402-6.
6. Tune LE, Steele C, Cooper T. Neuroleptic drugs in the management of behavioral symptoms of Alzheimer's disease. Psychiatr Clin North Am 1991;14:353-73.
7. Schneider LS, Pollock VE, Lyness SA. A meta-analysis of controlled trials of neuroleptic treatment in dementia. J Am Geriatr Soc 1990;38:553-63.
8. Lanctot KL, Best TS, Mittman N, et al. Efficacy and safety of neuroleptics in behavioral disorders associated with dementia. J Clin Psychiatry 1998;59:550-61.
9. Katz IR, Jeste DV, Mintzer JE, et al. Comparison of risperidone and placebo for psychosis and behavioral disturbances associated with dementia: a randomized, double-blind trial. J Clin Psychiatry 1999;60:107-15.
10. Borison RL, Davidson M, Berman I. Risperidone treatment in elderly patients with schizophrenia or dementia [poster]. Syllabus of the American Psychiatric Association's 46th Institute of Hospital and Community Psychiatry, 1994.
11. Gierz M, Ariane A, Jeste DV, et al. Use of risperidone in the elderly [poster]. Presented at the 9th annual meeting of the American Association for Geriatric Psychiatry, Tucson, AZ, February 16-19, 1996.
12. Goldberg RJ, Goldberg J. Risperidone for dementia-related disturbed behavior in nursing home residents: a clinical experience. Int Psychogeriatr 1997;9:65-8.
13. Lacro J, Eastham JH, Gilbert P, et al Use of risperidone in the elderly [abstr], Pharmacotherapy 1996;16:498.
14. Lavretsky H, Sultzer D. An open-label study of risperidone for the treatment of agitation in dementia [abstr]. Presented at the 149th annual meeting of the American Psychiatric Association, New York, NY, May 4-9, 1996.
15. Lemmens P, De Deyn P, De Smedt G. Risperidone in the treatment of behavioral disturbances in dementia [abstr|. Presented at the 36th annual meeting of the American College of Neuropsychopharmacology, Kamuela, HI, December 8-12, 1997.
16. Allen RL, Walker Z, D'Ath PJ, Katona CLE. Risperidone for psychotic and behavioral symptoms in Lewy body dementia [letter]. Lancet 1995;346:185.
17. Aronson SM, Lingham V, Slack M. Risperidone in the treatment of elderly psychiatric patients [poster]. Presented at the 19th annual symposium of the American Medical Directors Association, New Orleans, March 7-10, 1996.
18. Aronson SM. Cost-effectiveness and quality of life in psychosis: the pharmacoeconomics of risperidone. Clin Ther 1997;19:139-47.
19. Frenchman IB, Prince T. Effects of risperidone, haloperidol, and olanzapine on behavioral symptoms in nursing home patients [poster]. Presented at the 28th annual meeting of the American Society of Consultant Pharmacists, Philadelphia, PA, November 12-16, 1997.
20. Frenchman IB, Prince T. Clinical experience with risperidone, haloperidol, and thioridazine for dementia-associated behavioral disturbances in nursing home residents [poster]. Presented at the 27th annual meeting of the American Society of Consultant Pharmacists, Nashville, TN, November 13-17, 1996.
21. Irizarry MC, Ghaemi SN, Lee-Cherry ER, et al. Risperidone treatment of behavioral disturbances in outpatients with dementia. J Neuropsychiatry Clin Neurosci 1999;11:336-42.
22. Jeanblanc W, Davis YB. Risperidone for treating dementia-associated aggression [letter]. Am J Psychiatry 1995;152:1239.
23. Kopala LC, Honer WG. The use of risperidone in severely demented patients with persistent vocalizations. Int J Geriatr Psychiatry 1997;12:73-7.
24. Lee H, Cooney JM, Lawlor BA. The use of risperidone, an atypical neuroleptic, in Lewy body disease. Int J Geriatr Psychiatry 1994;9:415-17.
25. Madhusoodanan S, Brenner R, Araujo L, Abaza A. Efficacy of risperidone treatment for psychoses associated with schizophrenia, schizoaffective disorder, bipolar disorder, or senile dementia in 11 geriatric patients: a case series. J Clin Psychiatry 1995;56:514-18.
26. McKeith IG, Ballard CG, Harrison RW Neuroleptic sensitivity to risperidone in Lewy body dementia [letter]. Lancet 1995;346:699.
27. Zarate CA, Baldessarini RJ, Siegel AJ, et al. Risperidone in the elderly: a pharmacoepidemiologic study. J Clin Psychiatry 1997;58:311-17.
28. Cantillon M, Arvanitis LA, Miller BG, et al. Quetiapine fumarate reduces aggression [abstr]. In: Programs and abstracts on new research for the 151st meeting of the American Psychiatric Association, Toronto, Canada, May 30-June 4, 1998.
29. Schneider L, Yeung P, Sweitzer D, Arvanitis L. Quetiapine may reduce hostility in patients with psychoses related Alzheimer's disease. In: Abstracts of the International Congress on Schizophrenia Research biennial meeting, Santa Fe, NM, April 17-21, 1999.
30. Satterlee W, Tollefson G, Reams S, et al. A clinical update on olanzapine treatment in schizophrenia and in elderly Alzheimer's disease patients. In: Abstracts from the 35th annual NIMH New Clinical Drug Evaluation Unit Program, Orlando, FL, May 31-June 3, 1995.
31. Street J, Clark WS, Ganno KS, et al. Olanzapine reduces psychosis and behavioral disturbances associated with Alzheimer's disease. In: Abstracts from the 39th annual NIMH New Clinical Drug Evaluation Unit Program, Boca Raton, FL, June 1-4, 1999.
32. Oberholzer AF, Hendriksen C, Monsch AU, et al. Safety and effectiveness of low-dose clozapine in psychogeriatric patients: a preliminary study. Int Psychogeriatr 1992;4:187-95.
33. Salzman C, Vaccaro B, Lieff J, et al. Clozapine in older patients with psychosis and behavioral disruption. Am J Geriatr Psychiatry 1995;3:26-33.
34. Small JG, Milstein V, Marhenke JD, et al. Treatment outcome with clozapine in tardive dyskinesia, neuroleptic sensitivity, and treatment-resistant psychosis. J Clin Psychiatry 1987;48:263-7.
35. Frankenberg FR, Kalunian D. Clozapine in the elderly. J Geriatr Psychiatry Neurol 1994;7:131-4.
36. Mintzer JE. Clozapine in psychotic demented patients. In: New research program and abstracts of the annual meeting of the American Psychiatric Association, Philadelphia, PA, May 24, 1996.
37. Crismon ML, Dorson PG. Schizophrenia. In: DiPiro JT, Talbert RL, Yee GC, et al, eds. Pharmacotherapy: a pathophysiologic approach, 4th ed. Stanford, CT: Appleton & Lange, 1999;1118-40.
38. Jeste DV, Eastham JH, Lacro JP, et al. Management of late-life psychosis. J Clin Psychiatry 1996;57 (suppl 3):39-45.
39. Small GW, Rabins PV, Barry PP, et al. Diagnosis and treatment of Alzheimer disease and related disorders: consensus statement of the American Association for Geriatric Psychiatry, the Alzheimer's Association, and the American Geriatric Society. JAMA 1997;278:1363-71.
40. Rabins P. Practice guideline for the treatment of patients with Alzheimer's disease and other dementias of late life. Am J Psychiatry 1997;154 (suppl 5): 1-39.
41. Reisberg B, Borenstein J, Salob SP, et al. Behavioral symptoms in Alzheimer's disease: phenomenology and treatment. J Clin Psychiatry 1987;48 (suppl 5):9-15.
42. Cohen-Mansfield J, Marx MS, Rosenthal AS. A description of agitation in a nursing home. J Gerontol 1989;44:M77-84.
43. Cummings JL, Mega M, Gray K, et al. The neuropsychiatric inventory: comprehensive assessment of psychopathology in dementia. Neurology 1994;44:2308-14.